Phase 4 N=20 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
Granulomatosis With Polyangiitis · Microscopic Polyangiitis
Primary: Complete Remission — 14 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=70 The Effect of Deep Neuromuscular Block on Surgical Condition During Laparoscopic Colorectal Surgery
Neuromuscular Blockade
Primary: Number of Participants With Increased Intra-abdominal Pressure (IAP) Alarm as > 15 mmHg — 14; 6 Participants
Phase 4 N=2,825 A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)
Chronic Renal Anemia
Primary: Time to Composite of All-Cause Mortality and Non-Fatal Cardiovascular Events (Myocardial Infarction, Stroke) Defined as Time Between First Dose of Study Medication and…
Phase 4 N=224 Treatment of Bipolar Mania in Older Adults
Bipolar Disorder · Mania
Primary: Sedation Score — 0.5; 0.5; 0.6; 0.6 units on a scale
Phase 4 N=20 Internet Surveys and Their Impact on Adherence for Rosacea
Rosacea
Primary: Adherence (% of Prescribed Doses That Were Actually Taken by the Subject) — 8.2; 6.9 percentage of medication use
Phase 4 N=230 Safety Study of Intravenous Hydromorphone Using Incremental 1mg Doses up to 2mg for Adult ED Patients
Pain
Primary: Number of Patients Who Had Adequate Analgesia — 51; 172; 9; 35 Participants
Phase 4 N=50 Continuous Wound Infiltration After Hallux Valgus Surgery
Hallux Valgus
Primary: Average Postoperative Numeric Rating Scale (NRS) for Pain — 2.0; 1.9 units on a scale — p=0.596
Phase 4 N=671 Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents
Diphtheria · Tetanus · Acellular Pertussis
Primary: Anti-diphteria (Anti-D) and Anti-tetanus (Anti-T) Antibody Concentrations — 6.784; 6.493; 18.937; 18.515 IU/mL
Phase 4 N=60 Novartis Everolimus Transition
Graft Dysfunction · Interstitial Fibrosis
Primary: Kidney Allograft Fibrosis Assessment — 22.9; 20.8; 22.9; 27.8 % of fibrosis
Phase 4 N=67 ON-Q Pump Infusion of Ketorolac and Ropivacaine at the Wound Site for Postoperative Pain Management
Postoperative Pain
Primary: Pain Scores at Rest — 6.7; 6.2 units on a scale
Phase 4 N=85 Perineural Steroids for Peripheral Nerve Blocks
Osteoarthritis, Knee
Primary: Duration of Sensory Nerve Block — 37.00; 31.75; 29.67 hours
Phase 4 N=38 A Multicenter, 4-week Crossover (Total Duration 12 Weeks) to Determine the Impact of QVA149 on Nocturnal Oxygen Levels in Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Mean Night-time Blood Oxygenation — 89.59; 90.04 Percent Oxygenation — p=0.2419
Phase 4 N=444 Comparative Effectiveness of a Peer-led O2 Infoline for Patients and Caregivers
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Adherence to Supplemental O2 Prescription — 77; 73; 97 Participants
Phase 4 N=103 Long-term Persistence of Immunity to Hepatitis B in Adults Vaccinated With GlaxoSmithKline (GSK) Biologicals' Hepatitis B Vaccine (HBV), Engerix-B
Hepatitis B Vaccine
Primary: Percentage of Subjects With an Anamnestic Response to the HBV Challenge Dose, Based on the Last Available Time Point Before the Challenge Dose — 66.7; 85.3 Percentage of…
Phase 4 N=29 Substudy 'B' of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device #1 (MIND1)
Device Latency
Primary: Accuracy of Placebo-embedded IEM Detection by the MIND1 System Measured by the Percentage of Participants With IEM Detection Reported for Each of the 4 Time Points — 28…